Mometasone Zentiva (Mometasone Furoate Monohydrate)

Mometasone furoate monohydrate, the active ingredient in Mometasone Zentiva, is a corticosteroid (glucocorticoid) presented as a nasal spray for nasal use. It treats allergic rhinitis, seasonal allergic rhinitis and nasal polyps in adults and children as directed by a healthcare professional.

GNH USA supplies Mometasone Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometasone Zentiva, a nasal corticosteroid, is used to manage inflammatory conditions of the nasal passages. - Allergic rhinitis: reduces nasal congestion, itching and sneezing associated with seasonal and perennial allergies. - Seasonal allergic rhinitis: provides relief of symptoms triggered by pollen and other seasonal allergens. - Nasal polyps: helps shrink polyps and improve nasal airflow in patients with chronic nasal polyposis.

Mometasone Zentiva may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation or burning: mild discomfort at the site of application. - Headache: transient headache following use. - Epistaxis: occasional nosebleeds. - Throat irritation: soreness or dryness in the throat. - Cough: mild cough after administration.

Serious or Rare Side Effects: - Nasal septal perforation: rare tissue damage leading to perforation. - Secondary infection: fungal or bacterial infection of nasal mucosa. - Glaucoma or cataract: possible increased intra‑ocular pressure with prolonged use. - Adrenal suppression: systemic glucocorticoid effect with high‑dose or long‑term therapy. - Hypersensitivity reaction: severe allergic response such as angioedema.

Before prescribing Mometasone Zentiva, clinicians should consider several precautionary measures to ensure safe use. - Assess infection: avoid use in patients with active nasal or sinus infections without medical supervision. - Monitor duration: limit continuous use to the shortest period necessary, typically not exceeding several weeks. - Evaluate ocular health: patients with glaucoma or cataract risk should be monitored for intra‑ocular pressure changes. - Consider systemic exposure: caution in patients receiving other glucocorticoids to prevent additive effects. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Mometasone Zentiva can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Systemic corticosteroids: concurrent use may increase risk of systemic glucocorticoid effects such as adrenal suppression. - CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise local drug exposure and heighten side‑effect risk.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole): may modestly increase nasal mucosal concentrations. - Antihistamines: combined therapy may enhance overall allergy symptom control but requires monitoring for additive sedation (if first‑generation). - Nasal decongestants: concurrent use may increase local irritation. - Vaccines: live vaccines may have reduced efficacy if systemic absorption occurs; schedule appropriately.